{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T05:52:51Z","timestamp":1775886771153,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,26]]},"DOI":"10.7759\/cureus.32971","type":"journal-article","created":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T23:21:00Z","timestamp":1672096860000},"source":"Crossref","is-referenced-by-count":2,"title":["The Impact of Palliative Radiation Therapy on Patients With Advanced Gastric Cancer: Results of a Retrospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Atsuto","family":"Katano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideomi","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel RL","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022, 72:7-33. 10.3322\/caac.21708","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21114012","article-title":"Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies","volume":"21","author":"Machlowska J","year":"2020","unstructured":"Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020, 21:4012. 10.3390\/ijms21114012","journal-title":"Int J Mol Sci"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-022-01879-3","article-title":"Gastric cancer and genomics: review of literature","volume":"57","author":"Onoyama T","year":"2022","unstructured":"Onoyama T, Ishikawa S, Isomoto H. Gastric cancer and genomics: review of literature. J Gastroenterol. 2022, 57:505-16. 10.1007\/s00535-022-01879-3","journal-title":"J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2006.03.015","article-title":"Symptoms and diagnosis of gastric cancer at early curable stage","volume":"20","author":"Axon A","year":"2006","unstructured":"Axon A. Symptoms and diagnosis of gastric cancer at early curable stage. Best Pract Res Clin Gastroenterol. 2006, 20:697-708. 10.1016\/j.bpg.2006.03.015","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S149619","article-title":"Gastric cancer: epidemiology, prevention, classification, and treatment","volume":"10","author":"Sitarz R","year":"2018","unstructured":"Sitarz R, Skierucha M, Mielko J, Offerhaus GJ, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res. 2018, 10:239-48. 10.2147\/CMAR.S149619","journal-title":"Cancer Manag Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2010.05.014","article-title":"Outcome of palliative total gastrectomy for stage IV proximal gastric cancer","volume":"202","author":"Zhang JZ","year":"2011","unstructured":"Zhang JZ, Lu HS, Huang CM, et al.. Outcome of palliative total gastrectomy for stage IV proximal gastric cancer. Am J Surg. 2011, 202:91-6. 10.1016\/j.amjsurg.2010.05.014","journal-title":"Am J Surg"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-011-2056-x","article-title":"The value of palliative gastrectomy in gastric cancer with distant metastasis","volume":"19","author":"Chang YR","year":"2012","unstructured":"Chang YR, Han DS, Kong SH, Lee HJ, Kim SH, Kim WH, Yang HK. The value of palliative gastrectomy in gastric cancer with distant metastasis. Ann Surg Oncol. 2012, 19:1231-9. 10.1245\/s10434-011-2056-x","journal-title":"Ann Surg Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-020-00519-4","article-title":"Peri-operative outcomes and survival following palliative gastrectomy for gastric cancer: a systematic review and meta-analysis","volume":"52","author":"Cowling J","year":"2021","unstructured":"Cowling J, Gorman B, Riaz A, et al.. Peri-operative outcomes and survival following palliative gastrectomy for gastric cancer: a systematic review and meta-analysis. J Gastrointest Cancer. 2021, 52:41-56. 10.1007\/s12029-020-00519-4","journal-title":"J Gastrointest Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10061394","article-title":"Palliative Radiotherapy for Bleeding from Unresectable Gastric Cancer Using Three-Dimensional Conformal Technique","volume":"10","author":"Kawabata H","year":"2022","unstructured":"Kawabata H, Fujii T, Yamamoto T, et al.. Palliative Radiotherapy for Bleeding from Unresectable Gastric Cancer Using Three-Dimensional Conformal Technique. Biomedicines. 2022, 10:1394. 10.3390\/biomedicines10061394","journal-title":"Biomedicines"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08145-4","article-title":"Role of palliative radiotherapy in bleeding control in patients with unresectable advanced gastric cancer","volume":"21","author":"Yu J","year":"2021","unstructured":"Yu J, Jung J, Park SR, Ryu MH, Park JH, Kim JH, Yoon SM. Role of palliative radiotherapy in bleeding control in patients with unresectable advanced gastric cancer. BMC Cancer. 2021, 21:413. 10.1186\/s12885-021-08145-4","journal-title":"BMC Cancer"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-022-00943-2","article-title":"Palliative radiotherapy for gastric cancer bleeding: a multi-institutional retrospective study","volume":"21","author":"Takeda K","year":"2022","unstructured":"Takeda K, Sakayauchi T, Kubozono M, et al.. Palliative radiotherapy for gastric cancer bleeding: a multi-institutional retrospective study. BMC Palliat Care. 2022, 21:52. 10.1186\/s12904-022-00943-2","journal-title":"BMC Palliat Care"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15554","article-title":"Palliative radiotherapy for gastric cancer: a systematic review and meta-analysis","volume":"8","author":"Tey J","year":"2017","unstructured":"Tey J, Soon YY, Koh WY, et al.. Palliative radiotherapy for gastric cancer: a systematic review and meta-analysis. Oncotarget. 2017, 8:25797-805. 10.18632\/oncotarget.15554","journal-title":"Oncotarget"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-012-0200-3","article-title":"The successful endoscopic hemostasis factors in bleeding from advanced gastric cancer","volume":"16","author":"Koh KH","year":"2013","unstructured":"Koh KH, Kim K, Kwon DH, et al.. The successful endoscopic hemostasis factors in bleeding from advanced gastric cancer. Gastric Cancer. 2013, 16:397-403. 10.1007\/s10120-012-0200-3","journal-title":"Gastric Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1080\/13645706.2022.2111217","article-title":"Efficacy of local hemostatic agents after endoscopic submucosal dissection: a meta-analysis","volume":"31","author":"Jia Y","year":"2022","unstructured":"Jia Y, Zhai G, Wang E, Li P. Efficacy of local hemostatic agents after endoscopic submucosal dissection: a meta-analysis. Minim Invasive Ther Allied Technol. 2022, 31:1017-25. 10.1080\/13645706.2022.2111217","journal-title":"Minim Invasive Ther Allied Technol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019630","article-title":"Transcatheter arterial embolization for advanced gastric cancer bleeding: a single-center experience with 58 patients","volume":"99","author":"Cho SB","year":"2020","unstructured":"Cho SB, Hur S, Kim HC, et al.. Transcatheter arterial embolization for advanced gastric cancer bleeding: a single-center experience with 58 patients. Medicine (Baltimore). 2020, 99:e19630. 10.1097\/MD.0000000000019630","journal-title":"Medicine (Baltimore)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ags3.12439","article-title":"History and emerging trends in chemotherapy for gastric cancer","volume":"5","author":"Yamashita K","year":"2021","unstructured":"Yamashita K, Hosoda K, Niihara M, Hiki N. History and emerging trends in chemotherapy for gastric cancer. Ann Gastroenterol Surg. 2021, 5:446-56. 10.1002\/ags3.12439","journal-title":"Ann Gastroenterol Surg"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3370","article-title":"Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the keynote-062 phase 3 randomized clinical trial","volume":"6","author":"Shitara K","year":"2020","unstructured":"Shitara K, Van Cutsem E, Bang YJ, et al.. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the keynote-062 phase 3 randomized clinical trial. JAMA Oncol. 2020, 6:1571-80. 10.1001\/jamaoncol.2020.3370","journal-title":"JAMA Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang YK","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, et al.. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022, 23:234-47. 10.1016\/S1470-2045(21)00692-6","journal-title":"Lancet Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian YY","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al.. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021, 398:27-40. 10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/128962-the-impact-of-palliative-radiation-therapy-on-patients-with-advanced-gastric-cancer-results-of-a-retrospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:47:30Z","timestamp":1707508050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/128962-the-impact-of-palliative-radiation-therapy-on-patients-with-advanced-gastric-cancer-results-of-a-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,26]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.32971","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,26]]}}}